BMO Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Korro Bio(KRRO.US), With a Forecast Between $100 to $180
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO) and Gilead Sciences (GILD)
Korro Bio Price Target Cut to $95.00/Share From $105.00 by RBC Capital
Korro Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target
RBC Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $95
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $180
Buy Rating on Korro Bio Amid Strong KRRO-110 Preclinical Results and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: IO Biotech (IOBT), Gritstone Oncology (GRTS) and Korro Bio (KRRO)
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $100
Buy Rating Affirmed for Korro Bio Amid Promising KRRO-110 Preclinical Data and Superior Therapeutic Profile
HC Wainwright & Co. : The Korro Bio (KRRO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $100.00.
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target
Korro Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $100
Korro Bio Analyst Ratings
BMO Capital Maintains Outperform on Korro Bio, Maintains $120 Price Target
Bank of Montreal, Canada: Maintaining the Korro Bio (KRRO.US) rating, adjusted from superior to superior market rating, with a target price of $120.00.
No Data
No Data